Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Laying off 9 Percent of Workforce to Cut Operating Costs

NEW YORK – 23andMe said Friday that it will cut 75 jobs, or about 9 percent of its workforce.

In a filing with the US Securities and Exchange Commission, the consumer genomics and telehealth company disclosed that CEO Anne Wojcicki approved the layoffs on Friday. 23andMe did not indicate what kinds of positions would be eliminated but said that the cuts would be completed during the firm's fiscal first quarter, which ends June 30.

South San Francisco, California-based 23andMe expects the layoffs to reduce annual payroll and benefits expenditures by $12.8 million, according to the filing.

23andMe posted a net loss of $311.7 million in fiscal year 2023, which ended March 31, compared to a net loss of $217.5 million a year earlier. The company expects a net loss of $340 million to $365 million in FY 2024.

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.